Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06172491 · ClinicalTrials.gov registry record

Automating Delirium Severity in the ICU

A clinical trial of Delirium and Encephalopathy, sponsored by Mayo Clinic.

Recruiting
Registry status
400
Enrollment target
1
Study location

NCT06172491: Recruiting study of Delirium and Encephalopathy, sponsored by Mayo Clinic.

NCT06172491 is a study of Delirium and Encephalopathy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 400 participants, below the 881-participant average among 62 other Delirium trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06172491, a study of Delirium and Encephalopathy, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
400 participants
Enrollment target
1
Study location

Study Summary

The goal of this observational study is to develop a passive digital marker (PDM) for delirium severity and examine its performance in comparison to validated delirium severity tools in ICU patients \>50 years of age. The main questions it aims to answer are: * Is the trained convolutional neural network able to reliably measure delirium severity. * Is the Passive Digital Marker able to accurately measure delirium severity * Is the Passive Digital Marker acceptable and usable by frontline ICU nurse clinicians, patients, and their identified proxies (i.e., caregivers). Participants will: * Study participation involves a video camera recording you 24 hours per day while you are a patient in the Intensive Care Unit (ICU). * Study staff will visit you 4 times each day you are in the ICU. You will be asked questions each time they visit to train the digital marker and see differences between assessments and camera data.

Primary Outcome

The level of delirium severity will be measured by two types of prospective data collection. The first method is completed by study team members. A trained member of the study team will administer validated assessment tools 4xdaily from enrollment until ICU discharge or death. The Confusion Assessment Method for the Intensive Care Unit Severy Scale (CAM-ICU-7) is the gold standard for delirium severity measurement in the ICU. It is a 7-point scale, with 7 being severe delirium and 0 being no del

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2023-01-15
Est. Completion 2026-12-18
Mayo Clinic

2,844 total trials

What NCT06172491 shows while recruiting

NCT06172491 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 881-participant average among 62 other Delirium trials with a reported enrollment target (55% lower).

The record links to 3 conditions, with Delirium appearing as the primary indexed condition, and to 0 interventions.

NCT06172491 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06172491 about?

NCT06172491 is a clinical study titled "Automating Delirium Severity in the ICU". The goal of this observational study is to develop a passive digital marker (PDM) for delirium severity and examine its performance in comparison to validated delirium severity tools in ICU patients \>50 years of age. The main questions it aims to answer are: * Is the trained convolutional neural ...

What is the current status of trial NCT06172491?

This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2023-01-15. Estimated completion is 2026-12-18.

What conditions does trial NCT06172491 study?

This clinical trial studies the following conditions: Delirium, Encephalopathy, Intensive Care Unit Delirium.

Who is sponsoring clinical trial NCT06172491?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06172491 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Delirium

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06172491's enrollment target sits among peer trials

400 21st of 62 higher than 41 of 62 other Delirium trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Delirium trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06172491, the US trial registry maintained by the National Library of Medicine. NCT06172491 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.